Form 4: Procept BioRobotics CEO Reza Zadno Sells Shares Under 10b5-1 Trading Plan

Procept BioRobotics CEO Reza Zadno sold a total of 26,423 shares of common stock on December 4, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Reza Zadno, CEO of Procept BioRobotics, executed multiple sales of the company's common stock on December 4, 2024.
• These sales were conducted under a pre-established Rule 10b5-1 trading plan adopted on August 8, 2024.
• A total of 26,423 shares were sold in four separate transactions at weighted average prices ranging from $96.1532 to $99.0422.
• The sales resulted in a reduction of Zadno's direct holdings of Procept BioRobotics common stock from 173,885 to 152,762 shares.
• The weighted average prices for the transactions were $96.1532 for 5,300 shares, $97.011 for 13,762 shares, $98.0897 for 5,126 shares, and $99.0422 for 2,235 shares.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock sales under a pre-arranged plan, which is neither positive nor negative in itself. The sentiment is neutral.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially impacting investor sentiment.
• The reliance on a 10b5-1 trading plan suggests a pre-determined strategy for selling shares, which could continue in the future.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice for executives to avoid accusations of trading on non-public information. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the medical device and robotics sectors, such as Intuitive Surgical (ISRG) and Stryker (SYK).
• These plans allow for pre-scheduled sales of stock to avoid accusations of insider trading, and the reported transactions are consistent with standard practices.
• The volume of shares sold by Mr. Zadno is not unusual for an executive exercising a pre-planned trading strategy.

Stakeholder Impact

• The stock sales may have a minor impact on shareholder sentiment, but the pre-planned nature of the transactions should mitigate any significant concerns.
• The sales do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

insider trading, stock sale, Rule 10b5-1, executive compensation, Procept BioRobotics, Reza Zadno, PRCT